JP2011507852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507852A5 JP2011507852A5 JP2010539496A JP2010539496A JP2011507852A5 JP 2011507852 A5 JP2011507852 A5 JP 2011507852A5 JP 2010539496 A JP2010539496 A JP 2010539496A JP 2010539496 A JP2010539496 A JP 2010539496A JP 2011507852 A5 JP2011507852 A5 JP 2011507852A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- monoclonal antibody
- isolated monoclonal
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/005,054 US7906116B2 (en) | 2005-09-01 | 2007-12-20 | Methods for using and identifying modulators of Delta-like 4 |
| PCT/US2008/013899 WO2009085209A2 (en) | 2007-12-20 | 2008-12-19 | Methods for using and identifying modulators of delta-like 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507852A JP2011507852A (ja) | 2011-03-10 |
| JP2011507852A5 true JP2011507852A5 (https=) | 2012-02-23 |
Family
ID=40524791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539496A Pending JP2011507852A (ja) | 2007-12-20 | 2008-12-19 | デルタ様４のモジュレーターの利用及び同定方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7906116B2 (https=) |
| JP (1) | JP2011507852A (https=) |
| CN (1) | CN101970004A (https=) |
| CA (1) | CA2710082A1 (https=) |
| IL (1) | IL206502A0 (https=) |
| WO (1) | WO2009085209A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| US9567396B2 (en) * | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| WO2011053822A2 (en) | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| DK2066694T3 (en) * | 2006-09-29 | 2016-02-08 | Oncomed Pharm Inc | Compositions and Methods for Diagnosing and Treating Cancer |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG190572A1 (en) * | 2008-04-29 | 2013-06-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| TW201006485A (en) * | 2008-06-03 | 2010-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| CA2726087A1 (en) * | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CN102149825B (zh) | 2008-07-08 | 2015-07-22 | Abbvie公司 | 前列腺素e2双重可变结构域免疫球蛋白及其用途 |
| RU2011127198A (ru) * | 2008-12-04 | 2013-01-10 | Эбботт Лэборетриз | Иммуноглобулины с двойными вариабельными доменами и их применение |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| BR112012004546A8 (pt) | 2009-08-29 | 2017-12-05 | Abbott Lab | Terapêutica por proteínas ligantes dll4-ligantes |
| WO2011028811A2 (en) | 2009-09-01 | 2011-03-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
| HUE029661T2 (en) * | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| CA2782299A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| AU2014203172B2 (en) * | 2010-02-24 | 2016-03-10 | Immunogen, Inc. | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| TWI622402B (zh) | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| KR101853278B1 (ko) * | 2010-03-02 | 2018-05-02 | 애브비 인코포레이티드 | 치료학적 ｄｌｌ４ 결합 단백질 |
| EP3252072A3 (en) | 2010-08-03 | 2018-03-14 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
| JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 |
| MX357392B (es) * | 2012-04-02 | 2018-07-06 | Berg Llc | Ensayos basados en interrogatorios celulares y uso de los mismos. |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| TW202037609A (zh) | 2012-11-01 | 2020-10-16 | 美商艾伯維有限公司 | 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途 |
| WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
| ES2742855T3 (es) * | 2013-07-09 | 2020-02-17 | Ablbio | Nueva proteína de objetivo doble que se une específicamente a DLL4 y CEGF, y uso de la misma |
| GB201312727D0 (en) * | 2013-07-16 | 2013-08-28 | Isis Innovation | Modulators |
| CN114203296B (zh) | 2014-09-11 | 2025-10-17 | 布普格生物制药公司 | 基于患者数据的用于健康护理诊断和治疗的贝叶斯因果关系网络模型 |
| GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
| ES2808153T3 (es) | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US11679126B2 (en) | 2016-11-17 | 2023-06-20 | Chldren's Medical Center Corporation | Methods to enhance microvascular engraftment of bioengineered and primary tissues |
| CN112188901A (zh) * | 2018-03-15 | 2021-01-05 | 儿童医疗中心有限公司 | 用于治疗哮喘或变应性疾病的方法 |
| JP7669266B2 (ja) * | 2018-08-31 | 2025-04-28 | ウィスコンシン アラムニ リサーチ ファンデーション | 動脈内皮細胞を播種した血管移植片の生成 |
| WO2020223610A1 (en) * | 2019-05-01 | 2020-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineering broadly reactive human notch ligands as novel tools for biomedical applications |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| DE69638023D1 (de) | 1995-06-28 | 2009-10-22 | Univ Yale | Nukleotid- und proteinsequenzen von delta-genen von vertebraten und darauf basierende methoden |
| WO2002008284A2 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| AU6952498A (en) | 1997-04-04 | 1998-10-30 | Millenium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| US6121045A (en) | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| US6664098B1 (en) | 1997-05-14 | 2003-12-16 | Asahi Kasei Kabushiki Kaisha | Differentiation inhibitory agent |
| EP1100899A2 (en) | 1998-07-27 | 2001-05-23 | Amgen Inc. | Delta-related polypeptides |
| EP1181031A4 (en) | 1999-03-18 | 2005-07-20 | Childrens Medical Center | NOVEL ANTIANGIOGENIC PEPTIDES |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| AU2001292750B2 (en) | 2000-09-22 | 2005-07-14 | Genentech, Inc. | Notch receptor agonists and uses |
| CA2457879A1 (en) | 2001-08-22 | 2003-03-06 | Galapagos Genomics N.V. | Modulators of bone homeostasis identified in a high-throughput screen |
| JP2005518785A (ja) | 2001-11-14 | 2005-06-30 | ロランティス リミテッド | 内科療法 |
| AU2003226537A1 (en) | 2002-04-05 | 2003-10-27 | Lorantis Limited | Modulators of the notch signalling pathway and uses thereof in medical treatment |
| WO2004083372A2 (en) * | 2003-03-21 | 2004-09-30 | Lorantis Limited | Modulators of the notch signaling pathway immobilized on particles for modifying immune responses |
| EP1646400B1 (en) * | 2003-03-21 | 2010-07-21 | Celldex Therapeutics Limited | Treatment of allergic diseases using a modulator of the notch signaling pathway |
| US7837993B2 (en) * | 2004-03-19 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regeneration of aged skeletal muscle tissues |
| WO2006023209A2 (en) * | 2004-07-22 | 2006-03-02 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| JP2009507796A (ja) * | 2005-09-01 | 2009-02-26 | バスジーン セラピューティクス， インコーポレイテッド | デルタ様リガンド４のモジュレーターの利用及び同定方法 |
| CA2630839C (en) | 2005-12-16 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| EP2029159A2 (en) * | 2006-06-06 | 2009-03-04 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| NZ572177A (en) * | 2006-06-06 | 2012-02-24 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| DK2066694T3 (en) * | 2006-09-29 | 2016-02-08 | Oncomed Pharm Inc | Compositions and Methods for Diagnosing and Treating Cancer |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2120996A2 (en) | 2006-12-20 | 2009-11-25 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| WO2008091641A2 (en) * | 2007-01-24 | 2008-07-31 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
-
2007
- 2007-12-20 US US12/005,054 patent/US7906116B2/en not_active Expired - Fee Related
-
2008
- 2008-12-19 WO PCT/US2008/013899 patent/WO2009085209A2/en not_active Ceased
- 2008-12-19 CA CA2710082A patent/CA2710082A1/en not_active Abandoned
- 2008-12-19 JP JP2010539496A patent/JP2011507852A/ja active Pending
- 2008-12-19 CN CN2008801271728A patent/CN101970004A/zh active Pending
-
2010
- 2010-06-20 IL IL206502A patent/IL206502A0/en unknown
-
2011
- 2011-02-04 US US13/021,617 patent/US20110213127A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507852A5 (https=) | ||
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| EP0719859B1 (en) | Anti-alpha V-integrin monoclonal antibody | |
| JP6429771B2 (ja) | ｃ−Ｍｅｔに結合する抗原結合タンパク質 | |
| JP2023123596A (ja) | 癌の治療のためのクローディン１８．２に対する抗体を含む併用療法 | |
| JP5723420B2 (ja) | 癌の治療を目的とした抗ｃｄ１５１抗体の利用方法 | |
| HRP20201046T1 (hr) | Sastavi i metode za inhibitivnu aktivnost arginase | |
| BRPI0412478B8 (pt) | anticorpo que se liga ao igf-ir, composição farmacêutica e seu método de fabricação, linhagens celulares de hibridoma, ácido nucleico, vetor de expressão, célula hospedeira, 5 e métodos para a produção de um polipeptídeo que se liga ao igf-ir e inibe a ligação de igf-i e igf-ii ao igf-ir, e para a seleção de um anticorpo anti-igf-ir a partir de uma pluralidade de anticorpos anti-igf-ir | |
| Husmann et al. | Matrix Metalloproteinase 1 promotes tumor formation and lung metastasis in an intratibial injection osteosarcoma mouse model | |
| TW201728340A (zh) | 包含肽基之結合物及與其相關之方法 | |
| JP2010516708A5 (https=) | ||
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| HRP20170110T1 (hr) | Monoklonska protutijela | |
| JP2013512927A5 (https=) | ||
| MX2009012732A (es) | Anticuerpos anti-trop-2 humanizados e hibridos que median citotoxicidad de celulas cancerosas. | |
| RU2007141588A (ru) | Наночастица, и на ее основе инфузионный раствор и фармацевтическая композици | |
| BRPI0418765A (pt) | composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose | |
| Tucker et al. | Revisiting the tenascins: exploitable as cancer targets? | |
| Marty et al. | Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy | |
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| US20190106484A1 (en) | Antibody against peptide encoded by exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same | |
| JP2013541944A5 (https=) | ||
| WO2016207402A1 (en) | Proteins comprising a mutated lair-1 fragment and uses thereof | |
| RS64219B1 (sr) | Konjugati antitelo-lek usmereni prema uparap | |
| CN1288469A (zh) | 抗αv整联蛋白单克隆抗体及其在抑制αvβ6整联蛋白与纤连蛋白附着中的应用 |